101
|
Harbinski F, Craig VJ, Sanghavi S, Jeffery D, Liu L, Sheppard KA, Wagner S, Stamm C, Buness A, Chatenay-Rivauday C, Yao Y, He F, Lu CX, Guagnano V, Metz T, Finan PM, Hofmann F, Sellers WR, Porter JA, Myer VE, Graus-Porta D, Wilson CJ, Buckler A, Tiedt R. Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth. Cancer Discov 2012; 2:948-59. [DOI: 10.1158/2159-8290.cd-12-0237] [Citation(s) in RCA: 88] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
102
|
Lee NV, Lira ME, Pavlicek A, Ye J, Buckman D, Bagrodia S, Srinivasa SP, Zhao Y, Aparicio S, Rejto PA, Christensen JG, Ching KA. A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation. PLoS One 2012; 7:e39653. [PMID: 22745804 PMCID: PMC3382171 DOI: 10.1371/journal.pone.0039653] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2011] [Accepted: 05/24/2012] [Indexed: 12/19/2022] Open
Abstract
Targeting cancers with amplified or abnormally activated c-Met (hepatocyte growth factor receptor) may have therapeutic benefit based on nonclinical and emerging clinical findings. However, the eventual emergence of drug resistant tumors motivates the pre-emptive identification of potential mechanisms of clinical resistance. We rendered a MET amplified gastric cancer cell line, GTL16, resistant to c-Met inhibition with prolonged exposure to a c-Met inhibitor, PF-04217903 (METi). Characterization of surviving cells identified an amplified chromosomal rearrangement between 7q32 and 7q34 which overexpresses a constitutively active SND1-BRAF fusion protein. In the resistant clones, hyperactivation of the downstream MAPK pathway via SND1-BRAF conferred resistance to c-Met receptor tyrosine kinase inhibition. Combination treatment with METi and a RAF inhibitor, PF-04880594 (RAFi) inhibited ERK activation and circumvented resistance to either single agent. Alternatively, treatment with a MEK inhibitor, PD-0325901 (MEKi) alone effectively blocked ERK phosphorylation and inhibited cell growth. Our results suggest that combination of a c-Met tyrosine kinase inhibitor with a BRAF or a MEK inhibitor may be effective in treating resistant tumors that use activated BRAF to escape suppression of c-Met signaling.
Collapse
Affiliation(s)
- Nathan V. Lee
- Oncology Research Unit, Pfizer Global Research & Development, San Diego, California, United States of America
| | - Maruja E. Lira
- Oncology Research Unit, Pfizer Global Research & Development, San Diego, California, United States of America
| | - Adam Pavlicek
- Oncology Research Unit, Pfizer Global Research & Development, San Diego, California, United States of America
| | - Jingjing Ye
- Global Pre-Clinical Statistics, Pfizer Global Research & Development, San Diego, California, United States of America
| | - Dana Buckman
- Oncology Research Unit, Pfizer Global Research & Development, San Diego, California, United States of America
| | - Shubha Bagrodia
- Oncology Research Unit, Pfizer Global Research & Development, San Diego, California, United States of America
| | - Sreesha P. Srinivasa
- Oncology Research Unit, Pfizer Global Research & Development, San Diego, California, United States of America
| | - Yongjun Zhao
- Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, British Columbia, Canada
| | - Samuel Aparicio
- Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
- Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Paul A. Rejto
- Oncology Research Unit, Pfizer Global Research & Development, San Diego, California, United States of America
| | - James G. Christensen
- Oncology Research Unit, Pfizer Global Research & Development, San Diego, California, United States of America
| | - Keith A. Ching
- Oncology Research Unit, Pfizer Global Research & Development, San Diego, California, United States of America
- * E-mail:
| |
Collapse
|